Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

Ryohei Ogata(Kawasaki Medical School), Junichi Kurebayashi(Kawasaki Medical School)

Breast Cancer

August 28, 2020

10.1007/s12282-020-01150-8

Cited by 38

Related Papers

Anti‐cancer stem cell activity of a hedgehog inhibitor <scp>GANT</scp>61 in estrogen receptor‐positive breast cancer cells

|Cancer Science|2017|44

Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

|BMC Cancer|2010|43